Safety
How We Approach Peptide Safety.
The standards behind every protocol, from in-clinic compounding to provider review and patient follow-up.
How we think about safety
Peptide therapy works when the right molecule meets the right patient at the right dose, screened by a clinician who understands the trade-offs. Skip any one of those, and you have a guess. Our job is to make sure none of them are skipped.
Every prescription begins with an intake the patient fills out and a provider actually reads. We look for absolute contraindications first (active cancers, certain endocrine conditions, pregnancy), then for relative ones that might shift dose or sequence (recent surgery, current medications, lab values that need a baseline before we start). If the picture is unclear, we ask for more information rather than guessing.
Once the protocol is approved, the vials themselves come from our in-clinic compounding workflow with lot-level traceability and a Certificate of Analysis on file. After your first dose, follow-up is scheduled, not optional. Tolerability is reviewed at two weeks, progress at four to six, and a longer-horizon check at quarter marks. If a stop condition triggers, the protocol pauses while a provider reassesses.
The sections below break the same idea into the standards that govern each step and the questions patients ask us most often.
Our Standards
Third-Party Testing
Every batch is independently tested for identity, potency, and microbial contamination. Reports available on request.
Provider Review
Every protocol is reviewed by a licensed provider before dispensing, including stack interactions, dosing, and contraindications.
Sourcing & Compounding
We compound in-clinic from licensed pharmacies, with lot traceability from raw API through finished vial. No grey-market intermediaries.
Defined Stop Conditions
Every plan ships with explicit pause and discontinue criteria. If you hit any of them, the protocol stops while we reassess.
Patient Follow-Up
We follow up at intervals matched to the peptide's profile, with structured check-ins on tolerability, biomarkers, and progress toward goals.
Common Safety Questions
Statements on this page have not been evaluated by the FDA. This page is educational and does not constitute medical advice. Always consult a qualified provider before starting any new therapy.